BRPI1009381A2 - compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica - Google Patents
compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêuticaInfo
- Publication number
- BRPI1009381A2 BRPI1009381A2 BRPI1009381A BRPI1009381A BRPI1009381A2 BR PI1009381 A2 BRPI1009381 A2 BR PI1009381A2 BR PI1009381 A BRPI1009381 A BR PI1009381A BR PI1009381 A BRPI1009381 A BR PI1009381A BR PI1009381 A2 BRPI1009381 A2 BR PI1009381A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pharmaceutical composition
- trap1
- subject
- need
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN665MU2009 | 2009-03-23 | ||
US17135509P | 2009-04-21 | 2009-04-21 | |
IN2213MU2009 | 2009-09-23 | ||
US25194409P | 2009-10-15 | 2009-10-15 | |
IN2906MU2009 | 2009-12-16 | ||
US29447010P | 2010-01-12 | 2010-01-12 | |
PCT/IB2010/000930 WO2010109334A2 (en) | 2009-03-23 | 2010-03-23 | Thienopyrimidinedione derivatives as trpa1 modulators |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI1009381A2 true BRPI1009381A2 (pt) | 2016-06-21 |
BRPI1009381B1 BRPI1009381B1 (pt) | 2020-04-14 |
BRPI1009381B8 BRPI1009381B8 (pt) | 2021-05-25 |
Family
ID=42780205
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1013705A BRPI1013705A2 (pt) | 2009-03-23 | 2010-03-22 | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica |
BRPI1009381A BRPI1009381B8 (pt) | 2009-03-23 | 2010-03-23 | compostos, composição farmacêutica e uso de compostos e de composição farmacêutica |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1013705A BRPI1013705A2 (pt) | 2009-03-23 | 2010-03-22 | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica |
Country Status (23)
Country | Link |
---|---|
US (4) | US20120178766A1 (pt) |
EP (3) | EP2411395B1 (pt) |
JP (2) | JP2012521406A (pt) |
KR (2) | KR20110128898A (pt) |
CN (3) | CN102361874A (pt) |
AP (1) | AP2948A (pt) |
AU (2) | AU2010227225A1 (pt) |
BR (2) | BRPI1013705A2 (pt) |
CA (2) | CA2756535A1 (pt) |
DK (3) | DK2411395T3 (pt) |
EA (2) | EA201190138A1 (pt) |
ES (3) | ES2424341T3 (pt) |
HK (2) | HK1166074A1 (pt) |
HU (1) | HUE024538T2 (pt) |
IL (2) | IL215177A (pt) |
MX (1) | MX2011009822A (pt) |
PE (2) | PE20120834A1 (pt) |
PL (3) | PL2411395T3 (pt) |
PT (3) | PT2411395E (pt) |
SG (4) | SG184767A1 (pt) |
SI (3) | SI2411395T1 (pt) |
WO (2) | WO2010109329A1 (pt) |
ZA (2) | ZA201107649B (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010227225A1 (en) | 2009-03-23 | 2011-09-15 | Glenmark Pharmaceuticals, S.A. | Furopyrimidinedione derivatives as TRPA1 modulators |
UA108069C2 (uk) | 2009-03-23 | 2015-03-25 | Гленмарк Фармасьютікалс, С.А. | Злиті піримідиндіонові похідні як модулятори trpa1 |
MY159059A (en) * | 2010-12-20 | 2016-12-15 | Glenmark Pharmaceuticals Sa | 2-amino-4-arylthiazole compounds as trpa1 antagonists |
EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
BR112013032025A2 (pt) * | 2011-06-13 | 2016-12-20 | Glenmark Pharmaceutical S A | antagonistas trpa1, compostos ou seus sais farmaceuticamente aceitáveis, métodos para reduzir a quantidade de eosinófilos ou neutrófilos e/ou aumentar fev1 em indivíduo com distúrbio respiratório, para tratar distúrbio respiratório em indivíduo e/ou para identificar antagonista trpa1, usos de quantidade eficaz de antagonista trpa1, e composição farmacêutica para administração por inalação |
WO2012176143A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist |
WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
WO2013014597A1 (en) | 2011-07-25 | 2013-01-31 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
US20140364445A1 (en) * | 2011-12-05 | 2014-12-11 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent |
MY165622A (en) * | 2012-06-08 | 2018-04-18 | Glenmark Pharmaceuticals Sa | Amides of 2-amino-4aryl thiazole compounds and their salts |
CA2884922C (en) | 2012-10-01 | 2020-11-10 | Orion Corporation | N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists |
MX2015016024A (es) * | 2013-06-20 | 2016-04-04 | Glenmark Pharmaceuticals Sa | Formulacion en nanoparticulas que comprende un antagonista para trpa1. |
CA2926389A1 (en) | 2013-10-15 | 2015-04-23 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent |
WO2016023825A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[3,4-d]pyrimidine-2,4(1h,3h)-dione derivatives |
WO2016023831A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives |
EP3180345B1 (en) * | 2014-08-11 | 2018-10-10 | Hydra Biosciences, Inc. | Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders |
WO2016023830A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
WO2016028325A1 (en) | 2014-08-22 | 2016-02-25 | Duke University | Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch |
US20190175599A1 (en) * | 2014-09-16 | 2019-06-13 | Glemark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
US11229628B2 (en) | 2015-01-09 | 2022-01-25 | Duke University | TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch |
WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
JP2019513749A (ja) | 2016-04-07 | 2019-05-30 | デューク ユニバーシティ | 衛生化及び麻酔用のtrpv4及びtrpa1の小分子二重阻害剤 |
CN114874209A (zh) * | 2017-03-07 | 2022-08-09 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
CN109422749B (zh) * | 2017-08-21 | 2023-01-24 | 重庆医药工业研究院有限责任公司 | 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物 |
CN114671875A (zh) * | 2022-04-27 | 2022-06-28 | 成都施贝康生物医药科技有限公司 | 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途 |
CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2248231A1 (de) | 1972-10-02 | 1974-04-11 | Basf Ag | 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine |
SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
DE69912618T2 (de) * | 1998-08-28 | 2004-10-28 | Astrazeneca Ab | NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE |
ES2193839B1 (es) * | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
GB0118479D0 (en) * | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
AU2003288956A1 (en) * | 2002-10-30 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
US6890923B2 (en) * | 2002-12-16 | 2005-05-10 | Astrazeneca Ab | Compounds |
US7465581B2 (en) | 2002-12-18 | 2008-12-16 | The Scripps Research Institute | ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons |
SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
CA2536313A1 (en) | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
US20070099940A1 (en) | 2004-02-11 | 2007-05-03 | Spearing Paul K | Pth agonists |
US20070196866A1 (en) | 2004-03-13 | 2007-08-23 | Irm Llc | Modulators of ion channel trpa1 |
US20090062258A1 (en) | 2005-02-03 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
EP1928848A2 (en) * | 2005-08-04 | 2008-06-11 | Apogee Biothechnology Corporation | Sphingosine kinase inhibitors and methods of their use |
US20070105920A1 (en) * | 2005-11-08 | 2007-05-10 | Akzo Nobel N.V. | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives |
WO2007054480A1 (en) * | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
AU2006311036A1 (en) * | 2005-11-08 | 2007-05-18 | Msd Oss B.V. | 2-(benzimidazol-1-yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives useful in treatment of TRPV1 related disorders |
TWI423819B (zh) * | 2005-12-22 | 2014-01-21 | Hydra Biosciences Inc | 用於調節trpa1功能之化合物 |
TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
TW200836743A (en) | 2007-01-29 | 2008-09-16 | Xenon Pharmaceuticals Inc | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
EP3184527B1 (en) * | 2007-06-22 | 2020-01-29 | Eli Lilly and Company | 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel |
WO2009002983A1 (en) * | 2007-06-25 | 2008-12-31 | Sandisk Corporation | Non-volatile storage with individually controllable shield plates between storage elements |
WO2010004390A1 (en) | 2008-06-17 | 2010-01-14 | Glenmark Pharmaceuticals, S.A. | Quinazoline dione derivatives as trpa1 modulators |
WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
US8623880B2 (en) | 2009-03-23 | 2014-01-07 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
AU2010227225A1 (en) | 2009-03-23 | 2011-09-15 | Glenmark Pharmaceuticals, S.A. | Furopyrimidinedione derivatives as TRPA1 modulators |
SG174403A1 (en) | 2009-03-23 | 2011-10-28 | Glenmark Pharmaceuticals Sa | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators |
AR076332A1 (es) | 2009-04-21 | 2011-06-01 | Boehringer Ingelheim Int | Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones. |
CN102574860A (zh) | 2009-10-15 | 2012-07-11 | 辉瑞大药厂 | 吡咯并[2,3-d]嘧啶化合物 |
US8440710B2 (en) | 2009-10-15 | 2013-05-14 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AR079993A1 (es) | 2010-01-12 | 2012-03-07 | Ab Science | Derivados de azol, composiciones farmaceuticas y sus usos para tratar trastornos mediados por una sobreactividad de quinasas |
CN102666507B (zh) | 2010-07-13 | 2014-09-17 | 诺华股份有限公司 | 噁嗪衍生物及其在治疗神经病症中的用途 |
-
2010
- 2010-03-22 AU AU2010227225A patent/AU2010227225A1/en not_active Abandoned
- 2010-03-22 EP EP10716050.9A patent/EP2411395B1/en not_active Not-in-force
- 2010-03-22 PL PL10716050T patent/PL2411395T3/pl unknown
- 2010-03-22 PE PE2011001704A patent/PE20120834A1/es not_active Application Discontinuation
- 2010-03-22 US US13/257,280 patent/US20120178766A1/en not_active Abandoned
- 2010-03-22 SG SG2012069472A patent/SG184767A1/en unknown
- 2010-03-22 KR KR1020117022604A patent/KR20110128898A/ko not_active Application Discontinuation
- 2010-03-22 EA EA201190138A patent/EA201190138A1/ru unknown
- 2010-03-22 SI SI201030233T patent/SI2411395T1/sl unknown
- 2010-03-22 WO PCT/IB2010/000840 patent/WO2010109329A1/en active Application Filing
- 2010-03-22 JP JP2012501412A patent/JP2012521406A/ja active Pending
- 2010-03-22 PT PT107160509T patent/PT2411395E/pt unknown
- 2010-03-22 DK DK10716050.9T patent/DK2411395T3/da active
- 2010-03-22 SG SG2011066446A patent/SG174398A1/en unknown
- 2010-03-22 ES ES10716050T patent/ES2424341T3/es active Active
- 2010-03-22 CA CA2756535A patent/CA2756535A1/en not_active Abandoned
- 2010-03-22 CN CN2010800134701A patent/CN102361874A/zh active Pending
- 2010-03-22 BR BRPI1013705A patent/BRPI1013705A2/pt not_active IP Right Cessation
- 2010-03-23 US US12/936,451 patent/US8507503B2/en active Active
- 2010-03-23 CA CA2756536A patent/CA2756536C/en active Active
- 2010-03-23 ES ES10751712T patent/ES2424342T3/es active Active
- 2010-03-23 KR KR1020117022603A patent/KR101524337B1/ko active IP Right Grant
- 2010-03-23 SG SG2011066503A patent/SG174404A1/en unknown
- 2010-03-23 AP AP2011005889A patent/AP2948A/xx active
- 2010-03-23 JP JP2012501414A patent/JP5612070B2/ja active Active
- 2010-03-23 CN CN201080013463.1A patent/CN102361877B/zh active Active
- 2010-03-23 EA EA201190139A patent/EA022029B1/ru unknown
- 2010-03-23 ES ES13002731.1T patent/ES2532386T3/es active Active
- 2010-03-23 SI SI201030891T patent/SI2634191T1/sl unknown
- 2010-03-23 EP EP13002731.1A patent/EP2634191B1/en active Active
- 2010-03-23 SI SI201030231T patent/SI2411396T1/sl unknown
- 2010-03-23 PL PL13002731T patent/PL2634191T3/pl unknown
- 2010-03-23 EP EP10751712.0A patent/EP2411396B1/en active Active
- 2010-03-23 HU HUE13002731A patent/HUE024538T2/hu unknown
- 2010-03-23 DK DK10751712.0T patent/DK2411396T3/da active
- 2010-03-23 WO PCT/IB2010/000930 patent/WO2010109334A2/en active Application Filing
- 2010-03-23 PT PT107517120T patent/PT2411396E/pt unknown
- 2010-03-23 MX MX2011009822A patent/MX2011009822A/es unknown
- 2010-03-23 PT PT13002731T patent/PT2634191E/pt unknown
- 2010-03-23 PE PE2011001705A patent/PE20120775A1/es active IP Right Grant
- 2010-03-23 SG SG2012069530A patent/SG184769A1/en unknown
- 2010-03-23 BR BRPI1009381A patent/BRPI1009381B8/pt active IP Right Grant
- 2010-03-23 DK DK13002731T patent/DK2634191T3/en active
- 2010-03-23 CN CN201310628814.5A patent/CN103755720B/zh not_active Expired - Fee Related
- 2010-03-23 AU AU2010227230A patent/AU2010227230B2/en active Active
- 2010-03-23 PL PL10751712T patent/PL2411396T3/pl unknown
-
2011
- 2011-09-15 IL IL215177A patent/IL215177A/en not_active IP Right Cessation
- 2011-09-15 IL IL215175A patent/IL215175A/en active IP Right Grant
- 2011-10-19 ZA ZA2011/07649A patent/ZA201107649B/en unknown
- 2011-10-19 ZA ZA2011/07650A patent/ZA201107650B/en unknown
-
2012
- 2012-07-11 HK HK12106784.3A patent/HK1166074A1/xx not_active IP Right Cessation
- 2012-07-11 HK HK12106783.4A patent/HK1166073A1/xx unknown
-
2013
- 2013-06-25 US US13/925,975 patent/US8987278B2/en active Active
-
2015
- 2015-02-12 US US14/620,721 patent/US9474758B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1009381A2 (pt) | compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
CO6791606A2 (es) | Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas | |
BR112013020352A2 (pt) | composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo | |
BR112012015540A2 (pt) | composto, uso de composto, método para tratar um individuo, método de inibir janus quinases em um individuo, composição farmacêutica e combinação de produto | |
BRPI1013984A2 (pt) | composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto. | |
BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
BRPI0811542A2 (pt) | Composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e para tratar ou prevenir uma patologia relacionada com abeta em um mamífero composto, formulação farmacêutica, uso de um composto, e, métodos para inibir a atividade de bace, e, para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
BR112013019083A2 (pt) | combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença. | |
BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
BRPI0910963A2 (pt) | composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica | |
BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
BR112012008854A2 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano | |
BRPI0908503A2 (pt) | partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos | |
BRPI0919231A2 (pt) | agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades | |
BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI0922233A2 (pt) | compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI0811059A2 (pt) | combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação | |
BRPI1013396A2 (pt) | composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/04/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B25D | Requested change of name of applicant approved |
Owner name: ICHNOS SCIENCES SA (CH) |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |